177 related articles for article (PubMed ID: 32580593)
1. Current regional consensus recommendations on infant vaccination of the Latin American pediatric infectious diseases society (SLIPE).
Falleiros-Arlant LH; Torres JR; Lopez E; Avila-Agüero ML; Ulloa-Gutierrez R; Mascareñas A; Brea J
Expert Rev Vaccines; 2020 Jun; 19(6):491-498. PubMed ID: 32580593
[TBL] [Abstract][Full Text] [Related]
2. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
Falleiros-Arlant LH; Avila-Agüero ML; Brea del Castillo J; Mariño C
Rev Chilena Infectol; 2014 Oct; 31(5):590-603. PubMed ID: 25491459
[TBL] [Abstract][Full Text] [Related]
3. Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.
Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
Rev Chilena Infectol; 2019 Feb; 36(1):83-90. PubMed ID: 31095207
[TBL] [Abstract][Full Text] [Related]
4. [Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule].
Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
Rev Chilena Infectol; 2018 Aug; 35(4):395-402. PubMed ID: 30534926
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
6. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
Dolhain J; Janssens W; Mesaros N; Hanssens L; Fierens F
Expert Rev Vaccines; 2018 Jun; 17(6):513-524. PubMed ID: 29920121
[TBL] [Abstract][Full Text] [Related]
7. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
Lim FS; Han HH; Jacquet JM; Bock HL
Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229
[TBL] [Abstract][Full Text] [Related]
8. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
[TBL] [Abstract][Full Text] [Related]
9. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
Dolhain J; Janssens W; Dindore V; Mihalyi A
Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.
Tichmann-Schumann I; Soemantri P; Behre U; Disselhoff J; Mahler H; Maechler G; Sänger R; Jacquet JM; Schuerman L
Pediatr Infect Dis J; 2005 Jan; 24(1):70-7. PubMed ID: 15665713
[TBL] [Abstract][Full Text] [Related]
11. Latin American forum on immunization services during the COVID-19 pandemic.
Ávila-Agüero ML; Ospina-Henao S; Pirez MC; Gentile Á; Araya S; Brea J; Mendoza L; Falleiros-Arlant LH
Expert Rev Vaccines; 2021 Mar; 20(3):231-234. PubMed ID: 33554682
[No Abstract] [Full Text] [Related]
12. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
13. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
15. Risks of low vaccination coverage and strategies to prevent the resurgence of vaccine-preventable diseases in infants in the COVID-19 pandemic scenario: recommendations for Latin America and the Caribbean by the group of experts on infant immunization for Latin America.
Avila Agüero ML; Castillo JBD; Falleiros-Arlant LH; Berezín E; de Moraes JC; Torres-Martínez C; Lopez EL; Castillo ME; Laris-Gonzalez A; Solorzano F; Gentile A; Torres Torretti JP; López-Medina E
Expert Rev Vaccines; 2023; 22(1):1091-1101. PubMed ID: 37843489
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.
Gabutti G; Zepp F; Schuerman L; Dentico P; Bamfi F; Soncini R; Habermehl P; Knuf M; Crovari P;
Scand J Infect Dis; 2004; 36(8):585-92. PubMed ID: 15370670
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
Shao PL; Lu CY; Hsieh YC; Bock HL; Huang LM;
J Formos Med Assoc; 2011 Jun; 110(6):415-22. PubMed ID: 21741011
[TBL] [Abstract][Full Text] [Related]
18. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
[TBL] [Abstract][Full Text] [Related]
20. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
